Entero Therapeutics, Inc.
ENTO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $11 | $16 | $21 |
| G&A Expenses | $928 | $628 | $806 | $1,182 |
| SG&A Expenses | $928 | $628 | $806 | $1,182 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $935 | $639 | $821 | $1,204 |
| Operating Income | -$935 | -$639 | -$821 | -$1,204 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$36 | -$36 | -$127 | $9 |
| Pre-Tax Income | -$971 | -$675 | -$948 | -$1,194 |
| Tax Expense | $0 | $0 | $0 | $10,605 |
| Net Income | -$1,153 | -$998 | -$1,260 | -$12,238 |
| % Margin | – | – | – | – |
| EPS | -0.75 | -0.21 | -0.28 | -2.57 |
| % Growth | -257.1% | 25% | 89.1% | – |
| EPS Diluted | -0.75 | -0.21 | -0.28 | -2.57 |
| Weighted Avg Shares Out | 1,653 | 4,765 | 4,765 | 4,754 |
| Weighted Avg Shares Out Dil | 1,653 | 4,765 | 4,765 | 4,754 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $36 | $36 | $18 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$935 | -$639 | -$930 | -$1,204 |
| % Margin | – | – | – | – |